Systems-level design of a multi-epitope immunotherapeutic vaccine targeting EBV-associated oncogenesis
- 1PharmaQsar Bioinformatics Firm
- 2Department of Microbiology, School of Natural and Applied Sciences (SONAS), Kampala International University
Abstract
Epstein–Barr virus (EBV) is an oncogenic herpesvirus associated with multiple lymphoid and epithelial malignancies. Despite extensive investigation of EBV vaccine strategies, effective therapeutic approaches capable of targeting established EBV-associated cancers remain limited. In this study, we developed an integrated immunoinformatics and structure-guided framework for the design and prioritization of therapeutic multi-epitope vaccine candidates targeting both structural glycoproteins (gp350, gB, gH/gL, and gp42) and latency-associated proteins (EBNA1, LMP1, LMP2, and BZLF1). Sixteen multi-epitope vaccine constructs were generated and evaluated through sequence validation, structural refinement, reverse vaccinology assessment, immune-response simulation, receptor interaction analysis, molecular dynamics simulations, and expression-readiness profiling. The prioritized epitope repertoire achieved projected global population coverage exceeding 98% for both MHC class I and II pathways. Structural refinement improved model quality across vaccine constructs, while immunological and safety assessments supported favorable predicted antigenicity, non-allergenic potential, non-toxicity, and developability properties. Immune simulations predicted coordinated innate, humoral, and cellular responses, with several constructs demonstrating strong predicted immunogenic profiles. Molecular docking and molecular dynamics analyses further supported predicted structural compatibility and interaction stability with immune-associated receptors under simulated conditions. Integrated multi-parameter evaluation identified Constructs 4, 7, 10, 8, and 12 as the most promising candidates, with Construct 4 exhibiting the most balanced profile across immunological, structural, safety, and expression-related properties. Collectively, this study provides a comprehensive computational framework for therapeutic EBV vaccine development and identifies prioritized vaccine candidates for experimental validation. The proposed strategy offers a scalable approach for accelerating the development of multi-epitope vaccines targeting persistent viral infections and virus-associated malignancies.
Related
- Rational design of a multi-epitope vaccine targeting the stress-associated proteins for Mycoplasma fermentans via immunoinformatics
- Immunoinformatics design and in vitro evaluation of dendritic cell-targeting brucellosis multi-epitope vaccine based on Omp28 and GroEL
- The SKP2–Substrate Axis in Hematological Malignancies: Mechanisms of Oncogenesis and Opportunities for Targeted Therapy
- Next-Generation Liposomal and Nanoparticle-Based Systems for Glioblastoma: Molecular Targeting Strategies to Overcome the Blood–Brain Barrier
- Asymmetric DNA targeting by RNA-guided TIGR-Tas systems
BibTeX
@article{charles2026systemslevel,
title = {{Systems-level design of a multi-epitope immunotherapeutic vaccine targeting EBV-associated oncogenesis}},
author = {Ssemuyiga Charles and Naddamba Assumpta},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-62309-5},
url = {https://doi.org/10.1038/s41598-026-62309-5},
note = {CC BY},
}
RIS
TY - JOUR
TI - Systems-level design of a multi-epitope immunotherapeutic vaccine targeting EBV-associated oncogenesis
AU - Ssemuyiga Charles
AU - Naddamba Assumpta
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-62309-5
UR - https://doi.org/10.1038/s41598-026-62309-5
AB - Epstein–Barr virus (EBV) is an oncogenic herpesvirus associated with multiple lymphoid and epithelial malignancies. Despite extensive investigation of EBV vaccine strategies, effective therapeutic approaches capable of targeting established EBV-associated cancers remain limited. In this study, we developed an integrated immunoinformatics and structure-guided framework for the design and prioritization of therapeutic multi-epitope vaccine candidates targeting both structural glycoproteins (gp350, gB, gH/gL, and gp42) and latency-associated proteins (EBNA1, LMP1, LMP2, and BZLF1). Sixteen multi-epitope vaccine constructs were generated and evaluated through sequence validation, structural refinement, reverse vaccinology assessment, immune-response simulation, receptor interaction analysis, molecular dynamics simulations, and expression-readiness profiling. The prioritized epitope repertoire achieved projected global population coverage exceeding 98% for both MHC class I and II pathways. Structural refinement improved model quality across vaccine constructs, while immunological and safety assessments supported favorable predicted antigenicity, non-allergenic potential, non-toxicity, and developability properties. Immune simulations predicted coordinated innate, humoral, and cellular responses, with several constructs demonstrating strong predicted immunogenic profiles. Molecular docking and molecular dynamics analyses further supported predicted structural compatibility and interaction stability with immune-associated receptors under simulated conditions. Integrated multi-parameter evaluation identified Constructs 4, 7, 10, 8, and 12 as the most promising candidates, with Construct 4 exhibiting the most balanced profile across immunological, structural, safety, and expression-related properties. Collectively, this study provides a comprehensive computational framework for therapeutic EBV vaccine development and identifies prioritized vaccine candidates for experimental validation. The proposed strategy offers a scalable approach for accelerating the development of multi-epitope vaccines targeting persistent viral infections and virus-associated malignancies.
SN - 2045-2322
ER -